Cellectar Biosciences Inc (CLRB)
3.27
-0.06
(-1.80%)
USD |
NASDAQ |
May 07, 12:20
Cellectar Biosciences Cash from Investing (TTM): -0.864M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.864M |
September 30, 2023 | -0.7151M |
June 30, 2023 | -0.1249M |
March 31, 2023 | -0.1959M |
December 31, 2022 | -0.226M |
September 30, 2022 | -0.2379M |
June 30, 2022 | -0.2349M |
March 31, 2022 | -0.1714M |
December 31, 2021 | -0.1414M |
September 30, 2021 | -0.0288M |
June 30, 2021 | -0.0248M |
March 31, 2021 | -0.0518M |
December 31, 2020 | -0.0624M |
September 30, 2020 | -0.0509M |
June 30, 2020 | -0.054M |
March 31, 2020 | -0.0289M |
December 31, 2019 | -0.0245M |
September 30, 2019 | -0.3924M |
June 30, 2019 | -0.3443M |
March 31, 2019 | -0.3348M |
December 31, 2018 | -0.33M |
September 30, 2018 | 0.0436M |
June 30, 2018 | -0.0276M |
March 31, 2018 | -0.2818M |
December 31, 2017 | -0.3467M |
Date | Value |
---|---|
September 30, 2017 | -0.4137M |
June 30, 2017 | -0.3886M |
March 31, 2017 | -0.1386M |
December 31, 2016 | -0.0723M |
September 30, 2016 | -0.0239M |
June 30, 2016 | -0.029M |
March 31, 2016 | -0.033M |
December 31, 2015 | -0.0585M |
September 30, 2015 | -0.052M |
June 30, 2015 | -0.048M |
March 31, 2015 | -0.0398M |
December 31, 2014 | -0.0296M |
September 30, 2014 | -0.0303M |
June 30, 2014 | 1.808M |
March 31, 2014 | 1.808M |
December 31, 2013 | 1.852M |
September 30, 2013 | -0.1955M |
June 30, 2013 | -2.040M |
March 31, 2013 | -2.054M |
December 31, 2012 | -2.098M |
September 30, 2012 | -0.0434M |
June 30, 2012 | -0.1245M |
March 31, 2012 | 1.272M |
December 31, 2011 | 1.287M |
September 30, 2011 | 1.292M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-0.864M
Minimum
Dec 2023
-0.0245M
Maximum
Dec 2019
-0.2092M
Average
-0.1414M
Median
Dec 2021
Cash from Investing (TTM) Benchmarks
Perspective Therapeutics Inc | 24.37M |
Eli Lilly and Co | -7.642B |
Actinium Pharmaceuticals Inc | -0.088M |
Bristol-Myers Squibb Co | -21.70B |
Altimmune Inc | 13.73M |